The DESTINY-Breast03 study, a randomized, phase III trial pitting the antibody-drug conjugates trastuzumab emtansine and trastuzumab deruxtecan against each other in HER2+ metastatic breast cancer, found remarkable improvements in efficacy and safety for the latter, newer therapy.
个性的紫菜
oceanao
pcr163
苏卿
彭于彦祖
HEIKU
嗯哼
xjcy
shinysparrow
竹筏过海
Singularity
寻道图强
Yziii
梓泽丘墟
不配.
yufanhui
西红柿炒番茄
坚强的严青
哎嘿
Renee
皖公网安备34019202002308
